BE2017C009I2 - - Google Patents

Info

Publication number
BE2017C009I2
BE2017C009I2 BE2017C009C BE2017C009C BE2017C009I2 BE 2017C009 I2 BE2017C009 I2 BE 2017C009I2 BE 2017C009 C BE2017C009 C BE 2017C009C BE 2017C009 C BE2017C009 C BE 2017C009C BE 2017C009 I2 BE2017C009 I2 BE 2017C009I2
Authority
BE
Belgium
Application number
BE2017C009C
Other languages
Dutch (nl)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BE2017C009I2 publication Critical patent/BE2017C009I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
BE2017C009C 2000-04-14 2017-04-11 BE2017C009I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55008200A 2000-04-14 2000-04-14
US09/748,960 US20010046496A1 (en) 2000-04-14 2000-12-27 Method of administering an antibody

Publications (1)

Publication Number Publication Date
BE2017C009I2 true BE2017C009I2 (de) 2017-09-22

Family

ID=27069332

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C009C BE2017C009I2 (de) 2000-04-14 2017-04-11

Country Status (16)

Country Link
US (5) US20010046496A1 (de)
EP (3) EP3167902B1 (de)
JP (3) JP2003531129A (de)
AU (1) AU2001251629A1 (de)
BE (1) BE2017C009I2 (de)
CA (1) CA2406220C (de)
CY (3) CY1113489T1 (de)
DK (2) DK1278543T3 (de)
ES (2) ES2609689T3 (de)
FR (1) FR14C0080I2 (de)
HK (1) HK1054320A1 (de)
LU (1) LUC00014I2 (de)
MX (1) MXPA02010059A (de)
NL (1) NL300702I1 (de)
PT (1) PT2298348T (de)
WO (1) WO2001078779A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PL224150B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
MX350383B (es) * 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
CN104710532B (zh) 2004-09-03 2019-01-18 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
JP2009500390A (ja) 2005-07-08 2009-01-08 ファイザー・リミテッド 新規ＭＡｄＣＡＭ抗体
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
RU2008101383A (ru) * 2005-07-11 2009-07-20 Пфайзер Лимитед (GB) НОВАЯ КОМБИНАЦИЯ АНТИMAdCAM-АНТИТЕЛА И ПРОТИВОФИБРОЗНОГО ИНГИБИТОРА КАСПАЗЫ ДЛЯ ЛЕЧЕНИЯ ФИБРОЗА ПЕЧЕНИ
JP5478261B2 (ja) * 2007-01-11 2014-04-23 ノヴォ ノルディスク アクティーゼルスカブ 抗ｋｉｒ抗体、製剤、およびその使用
JP2010521966A (ja) * 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
US20110105724A1 (en) * 2007-08-16 2011-05-05 Stephanie Jane Clegg Novel compounds
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2723614C (en) * 2008-05-16 2015-07-14 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
KR101346530B1 (ko) * 2009-03-20 2013-12-31 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2862955T3 (es) 2010-10-01 2021-10-08 Modernatx Inc Acidos nucleicos manipulados y métodos de uso de los mismos
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ME02858B (de) * 2011-05-02 2018-04-20 Millennium Pharm Inc Formulierung für anti-4-7-antikörper
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9914779B2 (en) 2011-11-23 2018-03-13 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
EA201992881A3 (ru) * 2012-01-12 2020-12-30 Милленниум Фармасьютикалз, Инк. Композиция анти-47 антитела
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2833920A2 (de) 2012-04-02 2015-02-11 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von biologischen stoffen und proteinen in zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
EP3237004A4 (de) 2014-12-24 2018-06-13 Millennium Pharmaceuticals, Inc. Vorhersage des ausgangs einer behandlung mit einem anti-4-7-integrin-antikörper
CN109153721A (zh) 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
CN109071660A (zh) 2016-03-14 2018-12-21 千禧制药公司 预防移植物抗宿主疾病的方法
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
EP3452070A1 (de) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Dreifachkombinationstherapie zur behandlung von entzündlicher darmerkrankung
EP3468597A1 (de) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Verfahren zur behandlung von entzündlicher darmerkrankung
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
US20230139938A1 (en) * 2021-09-21 2023-05-04 University Of South Carolina Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1113810T3 (da) * 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding

Also Published As

Publication number Publication date
ES2609689T3 (es) 2017-04-21
JP6021959B2 (ja) 2016-11-09
US20010046496A1 (en) 2001-11-29
DK1278543T3 (da) 2013-01-14
EP1278543B1 (de) 2012-09-19
JP2012184241A (ja) 2012-09-27
CA2406220C (en) 2019-02-12
ES2398096T3 (es) 2013-03-13
FR14C0080I2 (fr) 2015-10-30
CY2014046I1 (el) 2016-04-13
CY1118429T1 (el) 2017-06-28
EP3167902A1 (de) 2017-05-17
CY1113489T1 (el) 2016-04-13
WO2001078779A3 (en) 2002-07-04
JP2003531129A (ja) 2003-10-21
EP2298348B1 (de) 2016-10-12
US20140186345A1 (en) 2014-07-03
US20050095238A1 (en) 2005-05-05
HK1054320A1 (en) 2003-11-28
LUC00014I2 (de) 2017-06-19
EP3167902B1 (de) 2020-07-29
EP2298348A1 (de) 2011-03-23
JP5764524B2 (ja) 2015-08-19
NL300702I2 (de) 2016-01-28
FR14C0080I1 (de) 2014-12-19
CA2406220A1 (en) 2001-10-25
CY2014046I2 (el) 2016-04-13
PT2298348T (pt) 2017-01-04
AU2001251629A1 (en) 2001-10-30
MXPA02010059A (es) 2004-08-19
DK2298348T3 (en) 2017-01-30
EP1278543A2 (de) 2003-01-29
WO2001078779A2 (en) 2001-10-25
JP2015083603A (ja) 2015-04-30
NL300702I1 (de) 2016-01-28
EP2298348B9 (de) 2017-02-15
LUC00014I1 (de) 2017-04-18
US20200002423A1 (en) 2020-01-02
US20120034243A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
LUC00014I1 (de)
BE2014C009I2 (de)
BE2013C060I2 (de)
BE2013C048I2 (de)
BE2012C026I2 (de)
BE2012C016I2 (de)
BE2011C032I2 (de)
JP2002537634A5 (de)
JP2002538777A5 (de)
JP2002537716A5 (de)
JP2003512904A5 (de)
JP2000316995A5 (de)
JP2001063310A5 (de)
JP2000227510A5 (de)
IN190849B (de)
JP2001256007A5 (de)
JP2001189881A5 (de)
JP2002541950A5 (de)
JP2002141967A5 (de)
JP2002050816A5 (de)
JP2003506708A5 (de)
JP2001196293A5 (de)
JP2001296414A5 (de)
JP2002011238A5 (de)
JP2002158917A5 (de)